{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T04:23:25Z","timestamp":1787027005787,"version":"build-2736575974"},"reference-count":63,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T00:00:00Z","timestamp":1760659200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Bladder cancer is a common and recurrent urologic malignancy. Although cystoscopy remains the diagnostic gold standard, its invasiveness, high cost, and limited patient compliance restrict its routine application. Non-invasive biomarkers have emerged as promising alternatives; however, their diagnostic performance has not yet been systematically compared across studies.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We searched PubMed, Embase, Web of Science, and the Cochrane Library for publications available until February 21, 2025. A total of 26 original studies on non-invasive diagnostic methods for bladder cancer were included. A Bayesian network meta-analysis was performed to compare biomarkers derived from urine and blood samples. Diagnostic performance was evaluated using sensitivity, specificity, diagnostic odds ratio (DOR), and the superiority index. Subgroup analyses were conducted for microRNAs and combined biomarker strategies. Study quality was assessed with the QUADAS-2 tool, and model convergence was verified using Rhat values.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Significant differences in biomarker performance were identified. In urine samples, angiogenin achieved the highest superiority index (5.28), while miR-125b was the best-performing microRNA (10.97). Combined detection strategies involving\n                      <jats:italic>TERT\/FGFR3\/TP53\/PIK3CA\/KRAS<\/jats:italic>\n                      demonstrated strong performance (8.54). In blood samples, miR-181b-5p and fibronectin had an index of 3.02, whereas miR-301a-3p exhibited the greatest superiority (50.71).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>This study is the first to systematically compare non-invasive bladder cancer biomarkers within a Bayesian framework. Specific microRNAs and combined detection strategies demonstrated robust diagnostic potential, providing a promising alternative to cystoscopy, particularly for early screening and patient monitoring.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Systematic review registration<\/jats:title>\n                    <jats:p>\n                      <jats:uri>https:\/\/www.crd.york.ac.uk\/PROSPERO\/<\/jats:uri>\n                      , identifier CRD420251018161.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fonc.2025.1649420","type":"journal-article","created":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T04:12:58Z","timestamp":1760674378000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":4,"title":["Integrated assessment of non-invasive diagnostic tools for bladder cancer: a network meta-analysis"],"prefix":"10.3389","volume":"15","author":[{"given":"Desheng","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bo","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junjiang","family":"Ye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yunjin","family":"Bai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ping","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,10,17]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21660","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J Clin"},{"key":"B2","doi-asserted-by":"publisher","first-page":"12","DOI":"10.3322\/caac.21820","article-title":"Cancer statistics, 2024","volume":"74","author":"Siegel","year":"2024","journal-title":"CA Cancer J Clin"},{"key":"B3","doi-asserted-by":"publisher","first-page":"1\u201312","DOI":"10.1615\/JEnvironPatholToxicolOncol.2022041342","article-title":"Comprehensive investigation of genes associated with cell cycle pathways for prognosis and immunotherapy in bladder urothelial carcinoma","volume":"41","author":"Mi","year":"2022","journal-title":"J Environ Pathol Toxicol Oncol"},{"key":"B4","article-title":"Bladder cancer: diagnosis and treatment","volume":"96","author":"Degeorge","year":"2017","journal-title":"Am Family Physician"},{"key":"B5","doi-asserted-by":"publisher","first-page":"e076743","DOI":"10.1136\/bmj-2023-076743","article-title":"Advances in diagnosis and treatment of bladder cancer","volume":"384","author":"Lopez-Beltran","year":"2024","journal-title":"BMJ (Clinical Res ed)"},{"key":"B6","doi-asserted-by":"publisher","first-page":"e176","DOI":"10.1002\/ctd2.176","article-title":"Urine-based liquid biopsy in bladder cancer: Opportunities and challenges","volume":"3","author":"Wang","year":"2023","journal-title":"Clin Trans Discov"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.7326\/M14-2385","article-title":"The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: checklist and explanations","volume":"162","author":"Hutton","year":"2015","journal-title":"Ann Internal Med"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-155-8-201110180-00009","article-title":"QUADAS-2: a revised tool for the quality assessment of diagnostic accuracy studies","volume":"155","author":"Whiting","year":"2011","journal-title":"Ann Internal Med"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1016\/j.jclinepi.2010.03.016","article-title":"Ioannidis J P A: Graphical methods and numerical summaries for presenting results from multiple-treatment meta-analysis: an overview and tutorial","volume":"64","author":"Salanti","year":"2011","journal-title":"J Clin Epidemiol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1177\/0962280216669182","article-title":"Anova model for network meta-analysis of diagnostic test accuracy data","volume":"27","author":"Nyaga","year":"2018","journal-title":"Stat Methods Med Res"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-051X.2011.01844.x","article-title":"A Bayesian network meta-analysis on comparisons of enamel matrix derivatives, guided tissue regeneration and their combination therapies","volume":"39","author":"Tu","year":"2012","journal-title":"J Clin Periodontol"},{"key":"B12","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1214\/20-BA1221","article-title":"Rank-normalization, folding, and localization: an improved $\\widehat[1]$ for assessing convergence of MCMC (with discussion)","volume":"16","author":"Vehtari","year":"2021","journal-title":"Bayesian Anal"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.6339\/JDS.2009.07(2).450","article-title":"Quantifying relative superiority among many binary-valued diagnostic tests in the presence of a gold standard","volume":"7","author":"Deutsch","year":"2009","journal-title":"J Data Sci"},{"key":"B14","doi-asserted-by":"publisher","first-page":"3814","DOI":"10.3390\/ijms21113814","article-title":"Urinary MicroRNAs as potential markers for non-invasive diagnosis of bladder cancer","volume":"21","author":"Erdmann","year":"2020","journal-title":"Int J Mol Sci"},{"key":"B15","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1186\/s40169-020-0257-2","article-title":"Detection of bladder cancer using urinary cell-free DNA and cellular DNA","volume":"9","author":"Ou","year":"2020","journal-title":"Clin Trans Med"},{"key":"B16","doi-asserted-by":"publisher","first-page":"4848752","DOI":"10.1155\/2020\/4848752","article-title":"The dependence between urinary levels of angiogenesis factors, 8-iso-prostaglandin f2\u03b1, \u0194-synuclein, and interleukin-13 in patients with bladder cancer: A pilot study","volume":"2020","author":"Szymanska","year":"2020","journal-title":"J Oncol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1007\/s11033-021-06451-5","article-title":"Urinary exosomal microRNA-96-5p and microRNA-183-5p expression as potential biomarkers of bladder cancer","volume":"48","author":"El-Shal","year":"2021","journal-title":"Mol Biol Rep"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.21037\/tcr-21-386","article-title":"Diagnostic and prognostic role of BTA, NMP22, survivin and cytology in urothelial carcinoma","volume":"10","author":"Gong","year":"2021","journal-title":"Trans Cancer Res"},{"key":"B19","doi-asserted-by":"publisher","first-page":"1293","DOI":"10.1186\/s12885-021-08926-x","article-title":"Urinary Exosomal miRNAs as biomarkers of bladder Cancer and experimental verification of mechanism of miR-93-5p in bladder Cancer","volume":"21","author":"Lin","year":"2021","journal-title":"BMC Cancer"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.7754\/Clin.Lab.2020.191020","article-title":"Evaluation of urine NDRG1 as noninvasive biomarker for bladder cancer diagnosis","volume":"67","author":"Sun","year":"2021","journal-title":"Clin Laboratory"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.26402\/jpp.2021.4.13","article-title":"The relationship between interleukin-13 and angiogenin in patients with bladder cancer","volume":"72","author":"Szymanska","year":"2021","journal-title":"J Physiol Pharmacol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.2147\/CMAR.S326732","article-title":"Mir-10a-5p: A promising biomarker for early diagnosis and prognosis evaluation of bladder cancer","volume":"13","author":"Yang","year":"2021","journal-title":"Cancer Manage Res"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.976329","article-title":"Urinary exosomal long non-coding RNAs as noninvasive biomarkers for diagnosis of bladder cancer by RNA sequencing","volume":"12","author":"Bian","year":"2022","journal-title":"Front Oncol"},{"key":"B24","doi-asserted-by":"publisher","first-page":"9038808","DOI":"10.1155\/2022\/9038808","article-title":"Urinary exosomal long noncoding RNA TERC as a noninvasive diagnostic and prognostic biomarker for bladder urothelial carcinoma","volume":"2022","author":"Chen","year":"2022","journal-title":"J Immunol Res"},{"key":"B25","article-title":"A four-miRNA signature in serum as a biomarker for bladder cancer diagnosis","volume":"14","author":"Li","year":"2022","journal-title":"Am J Trans Res"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.21037\/tcr-21-2611","article-title":"Identification of a three-miRNA panel in serum for bladder cancer diagnosis by a diagnostic test","volume":"11","author":"Li","year":"2022","journal-title":"Trans Cancer Res"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.2217\/fon-2022-0448","article-title":"Bladder cancer diagnosis with a four-miRNA panel in serum","volume":"18","author":"Li","year":"2022","journal-title":"Future Oncol"},{"key":"B28","doi-asserted-by":"publisher","first-page":"14319","DOI":"10.3390\/ijms232214319","article-title":"TERT promoter mutations as simple and non-invasive urinary biomarkers for the detection of urothelial bladder cancer in a high-risk region","volume":"23","author":"Pakmanesh","year":"2022","journal-title":"Int J Mol Sci"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1039\/D2MO00107A","article-title":"Comparative evaluation of long non-coding RNA-based biomarkers in the urinary sediment and urinary exosomes for non-invasive diagnosis of bladder cancer","volume":"18","author":"Qiu","year":"2022","journal-title":"Mol Omics"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1007\/s11010-022-04431-2","article-title":"Non-invasive diagnostic potential of microRNA-203 in liquid biopsy of urothelial carcinoma of bladder","volume":"477","author":"Singh","year":"2022","journal-title":"Mol Cell Biochem"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1007\/s12094-021-02741-3","article-title":"Diagnostic panel of serum miR-125b-5p, miR-182-5p, and miR-200c-3p as non-invasive biomarkers for urothelial bladder cancer","volume":"24","author":"Wen","year":"2022","journal-title":"Clin Trans Oncol"},{"key":"B32","doi-asserted-by":"publisher","first-page":"2565","DOI":"10.3390\/cancers15092565","article-title":"Diagnostic and prognostic roles of urine nectin-2 and nectin-4 in human bladder cancer","volume":"15","author":"Miyake","year":"2023","journal-title":"Cancers"},{"key":"B33","doi-asserted-by":"publisher","first-page":"115103","DOI":"10.1016\/j.jpba.2022.115103","article-title":"Application of surface plasmon resonance imaging biosensors for determination of fibronectin, laminin-5 and type IV collagen in serum of transitional bladder cancer patients","volume":"222","author":"Guszcz","year":"2023","journal-title":"J Pharm Biomed Anal"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1007\/s11033-023-08667-z","article-title":"The value of urinary exosomal lncRNA SNHG16 as a diagnostic biomarker for bladder cancer","volume":"50","author":"Liu","year":"2023","journal-title":"Mol Biol Rep"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.31557\/APJCP.2023.24.1.121","article-title":"Urine micro-RNA signature as a potential non-invasive diagnostic biomarker in bladder cancer","volume":"24","author":"Mamdouh","year":"2023","journal-title":"Asian Pacif J Cancer Prevent: APJCP"},{"key":"B36","doi-asserted-by":"publisher","first-page":"13890","DOI":"10.3390\/ijms241813890","article-title":"OncoUroMiR: Circulating miRNAs for Detection and Discrimination of the Main Urological Cancers Using a ddPCR-Based Approach","volume":"24","author":"Sequeira","year":"2023","journal-title":"Int J Mol Sci"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1080\/07853890.2023.2172206","article-title":"A serum miRNAs signature for early diagnosis of bladder cancer","volume":"55","author":"Yu","year":"2023","journal-title":"Ann Med"},{"key":"B38","doi-asserted-by":"publisher","first-page":"201313","DOI":"10.1016\/j.humgen.2024.201313","article-title":"Evaluation of miRNA 130a-3P and miRNA 301a-3P in Egyptian patients with urinary bladder carcinoma","volume":"41","author":"Abd El Gayed","year":"2024","journal-title":"Hum Gene"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1002\/kjm2.12845","article-title":"The value of urinary exosomal microRNA-21 in the early diagnosis and prognosis of bladder cancer","volume":"40","author":"Yang","year":"2024","journal-title":"Kaohsiung J Med Sci"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1016\/j.cellsig.2014.08.021","article-title":"Angiogenin interacts with ribonuclease inhibitor regulating PI3K\/AKT\/mTOR signaling pathway in bladder cancer cells","volume":"26","author":"Peng","year":"2014","journal-title":"Cell Signal"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1007\/s11912-023-01421-5","article-title":"An overview of angiogenesis in bladder cancer","volume":"25","author":"Elayat","year":"2023","journal-title":"Curr Oncol Rep"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.10097","article-title":"Angiogenin contributes to bladder cancer tumorigenesis by DNMT3b-mediated MMP2 activation","volume":"7","author":"Peres","year":"2016","journal-title":"Oncotarget"},{"key":"B43","doi-asserted-by":"publisher","first-page":"110780","DOI":"10.1016\/j.clinbiochem.2024.110780","article-title":"Investigating angiogenin\/ribonuclease 5 as a diagnostic biomarker for bladder cancer: In-depth analysis from a systematic review and meta-analysis","volume":"130","author":"Aalami","year":"2024","journal-title":"Clin Biochem"},{"key":"B44","doi-asserted-by":"publisher","first-page":"156926","DOI":"10.1016\/j.cyto.2025.156926","article-title":"MiR-125b suppresses bladder Cancer cell growth and triggers apoptosis by regulating IL-6\/IL-6R\/STAT3 axis in vitro and in vivo","volume":"190","author":"Lin","year":"2025","journal-title":"Cytokine"},{"key":"B45","doi-asserted-by":"publisher","first-page":"113","DOI":"10.3390\/medsci6040113","article-title":"New insights in bladder cancer diagnosis: urinary miRNAs and proteins","volume":"6","author":"Amuran","year":"2018","journal-title":"Med Sci (Basel Switzerland)"},{"key":"B46","doi-asserted-by":"publisher","first-page":"27","DOI":"10.3390\/cells9010027","article-title":"Fibronectin in cancer: friend or foe","volume":"9","author":"Lin","year":"2019","journal-title":"Cells"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1053\/j.seminoncol.2019.08.002","article-title":"Fibronectin in Malignancy: Cancer-specific alterations, protumoral effects, and therapeutic implications","volume":"46","author":"Rick","year":"2019","journal-title":"Semin In Oncol"},{"key":"B48","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1186\/s12957-018-1358-x","article-title":"Effectiveness of urine fibronectin as a non-invasive diagnostic biomarker in bladder cancer patients: a systematic review and meta-analysis","volume":"16","author":"Dong","year":"2018","journal-title":"World J Surg Oncol"},{"key":"B49","doi-asserted-by":"publisher","first-page":"e23517","DOI":"10.1002\/jcla.23517","article-title":"Evaluation of miR-130 family members as circulating biomarkers for the diagnosis of bladder cancer","volume":"34","author":"Wang","year":"2020","journal-title":"J Clin Lab Anal"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.3892\/ijo.2020.5072","article-title":"Upregulation of miRNA\u2212301a\u22123p promotes tumor progression in gastric cancer by suppressing NKRF and activating NF\u2212\u03baB signaling","volume":"57","author":"Xu","year":"2020","journal-title":"Int J Oncol"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.965231","article-title":"The role of miR-200 family in the regulation of hallmarks of cancer","volume":"12","author":"Klicka","year":"2022","journal-title":"Front Oncol"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1038\/s41388-019-1120-z","article-title":"Overexpressed miR-200a promotes bladder cancer invasion through direct regulating Dicer\/miR-16\/JNK2\/MMP-2 axis","volume":"39","author":"Yang","year":"2020","journal-title":"Oncogene"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1016\/j.urolonc.2024.01.018","article-title":"Survivin as a potential biomarker in the diagnosis of bladder cancer: A systematic review and meta-analysis","volume":"42","author":"Zhou","year":"2024","journal-title":"Urol Oncol Semin Original Invest"},{"key":"B54","doi-asserted-by":"publisher","first-page":"1959","DOI":"10.3390\/pharmaceutics13111959","article-title":"Role of survivin in bladder cancer: issues to be overcome when designing an efficient dual nano-therapy","volume":"13","author":"Arista-Romero","year":"2021","journal-title":"Pharmaceutics"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.3892\/ol.2019.11227","article-title":"Diagnostic accuracy of urinary survivin mRNA expression detected by RT-PCR compared with urine cytology in the detection of bladder cancer: A meta-analysis of diagnostic test accuracy in head-to-head studies","volume":"19","author":"Fu","year":"2020","journal-title":"Oncol Lett"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1097\/CEJ.0000000000000642","article-title":"The common region of lncRNAs UCA1 and UCA1\u03b1 contributes to the bladder cancer tumorigenesis","volume":"30","author":"Wang","year":"2021","journal-title":"Eur J Cancer Prevent: Off J Eur Cancer Prev Organisation (ECP)"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.7150\/ijbs.82875","article-title":"LncRNA UCA1 participates in de novo synthesis of guanine nucleotides in bladder cancer by recruiting TWIST1 to increase IMPDH1\/2","volume":"19","author":"Liu","year":"2023","journal-title":"Int J Biol Sci"},{"key":"B58","doi-asserted-by":"publisher","first-page":"e24805","DOI":"10.1097\/MD.0000000000024805","article-title":"lncRNA-UCA1 in the diagnosis of bladder cancer: A meta-analysis","volume":"100","author":"Ding","year":"2021","journal-title":"Medicine"},{"key":"B59","doi-asserted-by":"publisher","first-page":"9643139","DOI":"10.1155\/2017\/9643139","article-title":"The diagnostic value of nuclear matrix proteins in bladder cancer in the aspect of environmental risk from carcinogens","volume":"2017","author":"Szyma\u0144ska","year":"2017","journal-title":"BioMed Res Int"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.22065","article-title":"Evaluation of the NMP22 BladderChek test for detecting bladder cancer: a systematic review and meta-analysis","volume":"8","author":"Wang","year":"2017","journal-title":"Oncotarget"},{"key":"B61","doi-asserted-by":"publisher","first-page":"3360","DOI":"10.3390\/ijms21093360","article-title":"Diagnostic and prognostic potential of biomarkers CYFRA 21.1, ERCC1, p53, FGFR3 and TATI in bladder cancers","volume":"21","author":"Matuszczak","year":"2020","journal-title":"Int J Mol Sci"},{"key":"B62","doi-asserted-by":"publisher","first-page":"8597","DOI":"10.3390\/ijms23158597","article-title":"A liquid biopsy in bladder cancer-the current landscape in urinary biomarkers","volume":"23","author":"Matuszczak","year":"2022","journal-title":"Int J Mol Sci"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1093\/clinchem\/hvae156","article-title":"Machine learning-based detection of bladder cancer by urine cfDNA fragmentation hotspots that capture cancer-associated molecular features","volume":"70","author":"Meng","year":"2024","journal-title":"Clin Chem"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2025.1649420\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T04:13:00Z","timestamp":1760674380000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2025.1649420\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,17]]},"references-count":63,"alternative-id":["10.3389\/fonc.2025.1649420"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2025.1649420","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,17]]},"article-number":"1649420"}}